The complement system is recognised as a protector against blood-borne pathogens and a
controller of immune system and tissue homoeostasis. However, dysregulated complement …

The complement system was discovered at the end of the 19th century as a heat-labile
plasma component that “complemented” the antibodies in killing microbes, hence the name …

Background Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disease
characterized by chronic complement-mediated hemolysis. C5 inhibition controls …

Background Persistent hemolytic anemia and a lack of oral treatments are challenges for
patients with paroxysmal nocturnal hemoglobinuria who have received anti-C5 therapy or …

Ravulizumab, a new complement component C5 inhibitor administered every 8 weeks, was
noninferior to eculizumab administered every 2 weeks in complement-inhibitor–naive …

Abstract Ravulizumab (ALXN1210), a new complement C5 inhibitor, provides immediate,
complete, and sustained C5 inhibition. This phase 3, open-label study assessed the …

The treatment of paroxysmal nocturnal hemoglobinuria has been revolutionized by the
introduction of the anti-C5 agent eculizumab; however, eculizumab is not the cure for …

Dysregulation of the alternative complement pathway (AP) predisposes individuals to a
number of diseases including paroxysmal nocturnal hemoglobinuria, atypical hemolytic …

Eculizumab is the first and only medication approved for paroxysmal nocturnal
haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) treatment …

Background The haematological benefit of standard-of-care anti-C5 treatment for haemolytic
paroxysmal nocturnal haemoglobinuria is limited by residual intravascular haemolysis or …